Ask about this productRelated genes to: CYP1A2 antibody
- Gene:
- CYP1A2 NIH gene
- Name:
- cytochrome P450 family 1 subfamily A member 2
- Previous symbol:
- -
- Synonyms:
- P3-450, CP12
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-04-25
- Date modifiied:
- 2019-04-23
Related products to: CYP1A2 antibody
Related articles to: CYP1A2 antibody
- Obesity-related metabolic and hepatic alterations may influence drug metabolism via cytochrome P450 enzymes. While adult studies suggest altered CYP1A2 activity in obesity, data in pediatric populations remain limited and inconclusive. The objective was to assess the in vivo CYP1A2 phenotype in adolescents aged 11-18 years with and without obesity, and to explore sex-based differences in enzyme activity within this age group. In this open-label pharmacokinetic study, which is a part of the CYTONOX study, 65 adolescents aged 11-18 years were included, comprising 30 individuals with obesity and 35 without obesity, recruited based on feasibility. The CYP1A2 phenotype was assessed using urinary paraxanthine/caffeine metabolic ratios following caffeine exposure. Hepatic fat content was measured via magnetic resonance spectroscopy. The study received approval from the Danish Health Authorities (EudraCT: 2014-004554-34) and the Regional Ethical Committee of Zealand (SJ-455). Despite metabolic differences and increased hepatic fat in the obese group, the CYP1A2 phenotype did not differ significantly between obese and non-obese adolescents (mean log10 urinary metabolic ratio: 0.82 vs 0.80; P = .93). No sex-based differences were observed. Obesity in adolescents does not appear to significantly impact CYP1A2 phenotype assessed by urinary metabolic ratio, in contrast to selected studies in adults. These findings suggest preserved CYP1A2 function during adolescence despite metabolic and hepatic changes. Further longitudinal studies are needed to elucidate the age-related progression of hepatic enzyme activity in context of obesity. - Source: PubMed
Gade ChristinaUllah ShahidDalhoff KimAndersen Jon TrærupRiis TroelsHolm Jens ChristianLausten-Thomsen Ulrik - Sex and reproductive life-stage are currently not considered in (es)citalopram prescription guidelines, despite evidence of sex-related differences in its pharmacokinetics, tolerability, and therapeutic response. - Source: PubMed
Publication date: 2026/05/28
Bosch Eline Lde Beer FranciskaCath Danielle CGangadin Shiral STouw Daan JSommer Iris E C - Smoking tobacco cigarettes affects the metabolism of several antipsychotic medications by inducing CYP1A2 enzymes. Clozapine is particularly sensitive to this effect, as CYP1A2 induction increases the plasma clearance of the drug, resulting in lower clozapine plasma concentrations and a reduced clozapine concentration-dose (C/D) ratio than that in nonsmokers. Although the increase in clozapine concentrations and C/D ratios after smoking cessation is well-established, the effects of switching to e-cigarettes (electronic cigarettes or vapes) or initiating vaping without prior smoking is not well-understood. This review aimed to address these gaps. - Source: PubMed
Publication date: 2026/05/27
Uche Somtochukwu DRobson DeborahWalsh HannahTaylor EveMcNeill Ann - Amphetamine-type stimulants (ATS) represent a major segment of the global drugs of abuse market. Prolintane (1-(1-phenylpentan-2-yl)pyrrolidine), a substituted phenylethylamine ATS, was historically utilized as medication for several therapeutic indications. This study aimed to investigate the metabolic fate and urinary detectability of the three novel derivatives 2-, 3-, and 4-fluoroprolintane, which were recently shown to act as monoamine reuptake inhibitors. Liquid chromatography (LC)-high-resolution (HR) tandem mass spectrometry (MS/MS) was used for tentative identification of metabolites in rat urines (collected over a 24 h period following oral administration of 2 mg/kg fluoroprolintane isomer, each) or incubations with pooled human liver S9 fraction (1 h and 6 h, 25 µM fluoroprolintane isomer, each). Isozyme mapping was performed using individual incubations with 11 human phase I monooxygenases. The same rat urines were used for detectability studies using standard urine screening approaches (SUSA) by gas chromatography (GC)-mass spectrometry (MS), LC-ion trap MS, and LC-HRMS/MS. The fluoroprolintanes were extensively metabolized, with a total of 79 metabolites identified. Hydroxylations and subsequent oxidations were primarily mediated by CYP1A2, CYP2B6, CYP2C19, and CYP2D6, while glucuronidation and O-methylation were observed as main follow-up phase II reactions. All three SUSA allowed detection, primarily via metabolites. However, the high degree of metabolic overlap will make isomer differentiation challenging. These findings contribute to a comprehensive risk assessment and provide critical reference data for clinical and forensic laboratories to identify these substances in biological specimens. - Source: PubMed
Publication date: 2026/05/25
Wagmann LeaHerter AnicaDybek Michael BAdejare AdeboyeWallach JasonBrandt Simon DMeyer Markus R - To provide an updated and integrative evaluation of duloxetine as a potential therapeutic agent for irritable bowel syndrome (IBS), with emphasis on its mechanisms of action across the gut-brain axis. The review addresses the key research question: Can duloxetine, beyond its antidepressant effects, modulate neuroimmune, microbial, and pharmacogenomic factors relevant to IBS, particularly pain-predominant subtypes? This narrative review provides a targeted synthesis of selected preclinical, clinical, and translational literature addressing duloxetine as a potential gut-brain axis modulator in irritable bowel syndrome. Evidence related to neuroimmune mechanisms, microbiota-related pathways, pharmacogenomic considerations, and clinical studies was narratively summarized. Evidence indicates that duloxetine modulates serotonergic and noradrenergic neurotransmission, decreases visceral hypersensitivity, and attenuates neuroinflammation via inhibition of microglial P2X4/NF-κB signaling. Duloxetine also shifts cytokine balance toward an anti-inflammatory profile (↑ IL-10, ↓ IL-6, ↓ TNF-α). Emerging data suggest additional benefits through modulation of gut microbiota composition, enhancement of short-chain fatty acid (SCFA) production, and improvement of intestinal barrier integrity. Pharmacogenomic factors, especially CYP2D6 and CYP1A2 polymorphisms, significantly influence duloxetine metabolism and therapeutic response. Compared with TCAs and SSRIs, duloxetine shows more favorable efficacy in relieving combined gastrointestinal and psychological symptoms with fewer sexual side effects. Duloxetine exhibits multifaceted actions that extend beyond mood regulation, positioning it as a promising but still investigational GBA-directed option dual-action therapy within the gut-brain axis framework. The collective findings support the need for biomarker-guided clinical trials incorporating microbiota profiling, cytokine signatures, and pharmacogenetic testing to validate duloxetine's role in precision-medicine-based IBS management. - Source: PubMed
Publication date: 2026/05/22
Rejili MokhtarMustafa Aya MAl-Kuraishy Hayder MHussein Nawar RAl-Maiahy Thabat JAl-Gareeb Ali IAlbuhadily Ali KBatiha Gaber El-Saber